Search
for
Sort by
Research 30 of 1000+
- Long-term efficacy and safety of the dual 5-alpha reductase blocker dutasteride on male androgenetic alopecia patients
- Impact of Alpha Blockers, 5-alpha Reductase Inhibitors and Combination Therapy on Sexual Function
- Do Alpha-Blockers and 5-Alpha Reductase Inhibitors Increase Dementia Risk? A Network Meta-analysis
- Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α-Blockers and 5-Alpha Reductase Inhibitors
- IsoPSA Performance Characteristics are Unaffected by 5-Alpha Reductase Inhibitors or Alpha-Blockers: Results From the IsoPSA Validation Study
- Alpha Blocker and 5-Alpha Reductase Inhibitor Prescribing Habits among Urologists and Primary Care Physicians
- Benign Prostatic Hyperplasia Pharmacotherapy and Incident Ocular Surface Disease: Comparative Risk of Alpha-Blockers vs 5-Alpha Reductase Inhibitors
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Review: Adding α<sub>1</sub>-blockers to 5α-reductase inhibitors improves lower urinary tract symptoms in men
- 5-Alpha-Reductase Inhibitors and Combination Therapy
- Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature
- The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
- Analysis of Data From Breast Diseases Treated With 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia
- Depression risk of 5-alpha reductase inhibitors: impact of active-comparator versus non-drug user control groups on risk measurement
- Depression risk of 5-alpha reductase inhibitors: A systematic review and meta-analysis with a focus on comparator groups
- No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study
- MP09-16 5-ALPHA REDUCTASE INHIBITORS FOR MALE LOWER URINARY TRACT SYMPTOMS: A COCHRANE SYSTEMATIC REVIEW AND META-ANALYSIS
- Faculty Opinions recommendation of Association between 5-alpha reductase inhibition and risk of hip fracture.
- Immunolocalization of 5α-Reductase Isozymes in Acne Lesions and Normal Skin
- Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors
- Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs
- 5‐α reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population‐based cohort study
- Influencia del tratamiento con alfa bloqueantes e inhibidores de la 5 alfa reductasa en los hallazgos morfológicos e inmunohistoquímicos de la hiperplasia benigna de próstata
- 5‐Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety
- An update on the use of 5alpha-reductase inhibitors
- In vivo evidence for an increase in 5alpha‐reductase activity in the rat central nervous system following morphine exposure
- Efficacy and safety of α-blockers plus 5α-reductase inhibitors for benign prostatic hyperplasia: a systematic review and meta-analysis
- Medikamentöse Therapie der BPH Ist eine Kombinationstherapie mit 5α-Reduktasehemmern und α-Rezeptorenblockern sinnvoll?